Appeal Letter (Denied Cancer Therapy)

Header and Routing Information

[Treating clinician full name, credentials]
[Specialty]
[Facility/clinic name]
[Street address line 1]
[Street address line 2] (Only include if applicable)
[City, State ZIP]
Direct phone: [Direct clinician/clinic phone]
Fax: [Clinician/clinic fax]
NPI: [Clinician NPI]

[Date of submission]

[Health plan name]
[Department: Medical Director / Appeals Department / as specified on denial notice]
[Submission address line 1]
[Submission address line 2] (Only include if applicable)
[City, State ZIP]
Fax: [Appeals submission fax] (Only include if available)

Re:
Patient: [Patient full legal name] | DOB: [Date of birth]
Member/Policy ID: [Member ID or "Not available"] | Group #: [Group number or "Not available"]
Claim or Authorization Request ID: [Claim/auth ID or "Not available"]
Date of Denial Notice: [Date or "Not available"]
Requested Therapy Start Date: [Date or "Not available"]
Ordering Provider: [Ordering provider full name, credentials] | NPI: [NPI or "Not available"]
Requested Therapy: [Drug/biologic name] at [dose, route, schedule/cycle length] for [number of cycles or duration]
Relevant Codes: ICD-10: [Code(s) or "Not available"]; CPT/HCPCS: [Code(s) or "Not available"]

Appeal Type: [Standard Appeal / Expedited/Urgent Appeal]
(If expedited/urgent, include:) Urgency justification: [Clinical justification for urgent review and latest safe start date]

Executive Summary

(Provide 4–6 concise sentences in professional, neutral tone. Quote key payer phrases briefly.)

The denial notice states "[Brief quoted denial reason from payer]." [Patient name] has [cancer type, histology, stage with date, and key biomarkers/molecular features]. [Requested therapy name/regimen] is requested to begin [intended start date or timeframe]. [One sentence explaining why therapy is medically necessary now, tied to disease status, biomarkers, prior therapy, or clinical goals]. Action requested: [Approve coverage / Overturn denial / Authorize X cycles through Y date / Grant step-therapy exception / Approve site-of-care exception]. (If urgent, add:) [Brief statement of potential harm from delay, framed probabilistically and patient-specific].

Clinical Summary

(Include only information available in the record. Do not infer staging or biomarker status. Use dates where available.)

• Primary cancer: [Cancer type] | Histology/grade: [Histology, grade] | Stage: [Stage, clinical/pathologic] (Established [date]).
• Disease status: [Newly diagnosed / Adjuvant / Locally advanced / Metastatic / Relapsed-refractory].
• Sites of disease: [Sites as documented on imaging with dates] (See [Exhibit label(s)]).
• Biomarkers/Molecular findings: [Marker and result, e.g., PD-L1 %, MSI status, EGFR, HER2, BRCA] from [specimen type, date]. (If pending:) [Pending results and expected date].
• Performance status: [ECOG or Karnofsky score and date]. (If not formally documented, describe functional status from notes.)
• Organ function/comorbidities relevant to therapy selection: [Renal/hepatic function, cardiac status, neuropathy, autoimmune disease, infection risk, other comorbidities; include any contraindications to alternatives].

Prior oncologic therapies: (List in chronological order)

• [Line 1 regimen name] ([Start date]–[End date]); Best response: [CR / PR / SD / PD]; Discontinued due to: [Progression / Toxicity / Completion / Other]; Toxicities limiting re-use: [Toxicities or "None"].
• [Line 2 regimen name] ([Start date]–[End date]); Best response: [Response]; Discontinued due to: [Reason]; Toxicities: [Details].
• (Add additional lines as applicable.)

• Current request context: [Initiation / Continuation of previously approved therapy / Dose modification / Supportive agent].
• Therapy interruption: [None / Interrupted since (date) due to denial]. (If interrupted, describe clinical impact.)

Denial Rationale and Rebuttal

(Create a separate subsection for each reason cited by the payer. Use the payer's exact criterion wording in brief quotation marks. For each reason, present the payer requirement, patient-specific facts, supporting evidence, and why payer-preferred alternatives are inappropriate when applicable. Reference exhibits consistently.)

[Denial Reason 1: "Quoted payer criterion/statement"]

• Payer requirement/criterion: [Restate criterion succinctly with brief quoted phrase(s) from denial].
• Patient-specific facts: [Relevant clinical data that address the criterion; cite exhibits, e.g., (See Exhibit A: Denial Notice; Exhibit B: Pathology; Exhibit C: Imaging report)].
• Supporting evidence: [Guideline name/version and recommendation category], [Compendia entry and category if applicable], [Key study(ies) with outcome data].
• Why payer-preferred alternative is inappropriate: (Include if applicable)
  • [Contraindication or safety concern specific to patient].
  • [Prior failure or intolerance with dates/toxicity].
  • [Inferior efficacy given biomarkers/disease context with evidence citation].
  • [Risk of clinically unsafe delay with mandated step therapy].

[Denial Reason 2: "Quoted payer criterion/statement"]

(Repeat structure above for additional denial reasons as needed.)

Harms of Delay or Omission

(Use patient-specific, probabilistic language. Include time sensitivity. If therapy is ongoing, describe harms of interruption.)

• Delay beyond [timeframe] is likely to result in [disease progression at specific sites / loss of local control / loss of resectability].
• [Risk of declining performance status that could preclude future therapy options].
• [Increased risk of hospitalization or symptom crisis, e.g., pain, bleeding, obstruction].
• [Biologic/aggressive features heightening urgency: high-grade histology, high tumor burden, rapid progression, high-risk stage, adverse molecular profile].
• (If therapy interrupted:) [Risk of disease flare, loss of response, or resistance development with treatment gap].

Evidence and Guideline Support

(Cite the most authoritative sources concisely. Prefer national guidelines, recognized compendia, and peer-reviewed full publications; do not cite abstracts alone.)

• Guidelines: [Guideline organization, disease-specific guideline name, version/date] — [Recommendation for requested therapy/sequence; category/strength if available].
• Compendia: (For off-label use) [Compendium name] — [Indication wording], [Evidence category/strength].
• Key study 1: [First author et al., Journal, Year, PMID/DOI] — [Study population], [Key endpoints: OS/PFS/ORR], [Relevance to patient].
• Key study 2: [Citation] — [Relevance and outcomes].
• Key study 3: (Optional) [Citation] — [Relevance and outcomes].

Requested Action and Contact Information

I respectfully request approval and authorization of [Requested therapy name] at [dose, schedule] for [number of cycles or duration] beginning [start date or "as soon as approved"]. [Specific exceptions requested: step-therapy override / site-of-care exception / out-of-network authorization / continuation of therapy]. (Include as applicable.)

(If expedited review requested:) Expedited/Urgent Appeal Request: [Clinical deadline and rationale for expedited timeline].

I am available for a peer-to-peer discussion at [Direct phone] during [Preferred contact window and time zone]. Please ensure the reviewing physician is board-certified in medical oncology with expertise in [Cancer type]. If this appeal is denied, please provide written rationale including the specific criteria and guidelines used. We intend to pursue the next level of appeal or external review if necessary.

Attachments Index

(Label each document and reference these exhibit labels throughout the letter.)

• Exhibit A: Denial Notice — [Date] — Payer's stated reasons and criteria.
• Exhibit B: Prior Authorization Request and Submitted Clinicals — [Date] — Initial request and clinical justification.
• Exhibit C: Pathology Report — [Specimen date] — Diagnosis, histology, grade, biomarkers.
• Exhibit D: Molecular/Biomarker Results — [Test name(s), date(s)] — Results relevant to therapy selection.
• Exhibit E: Imaging Reports — [Modality, dates] — Staging/restaging findings and disease sites.
• Exhibit F: Oncology Progress Notes — [Date range] — Performance status, treatment plan, clinical course.
• Exhibit G: Prior Therapy Records — [Regimens, dates] — Responses and toxicities.
• Exhibit H: Guideline Excerpts — [Organization, version/date] — Recommendation supporting requested therapy.
• Exhibit I: Compendia Entry — [Compendium name, date] — Off-label support and evidence category. (If applicable.)
• Exhibit J: Key Peer-Reviewed Articles — [Citations] — Full-text attached.

Closing

Based on the patient's diagnosis, clinical status, and the evidence summarized above, it is my professional opinion that the requested therapy is medically necessary at this time. Reasonable alternatives were considered and are inappropriate as outlined. Delay or omission poses clinically meaningful risk to the patient. I appreciate your prompt attention to this appeal and remain available for further discussion.

Sincerely,
[Treating clinician full name, credentials]
[Specialty]
[Facility/clinic name]
[Date]